Why the Ramsay (ASX:RHC) share price is outperforming the ASX today

The Ramsay share price is beating the market gloom after striking a new agreement.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price is beating the market gloom this morning after striking a new agreement with the UK's National Health Service.

Shares in the hospital operator jumped 1.7% to $68.38 during lunchtime trade. That stands in contrast to the 0.6% dive by the S&P/ASX 200 Index (ASX: XJO).

Ramsay announced after the market closed yesterday that it reached a new volume-based agreement with NHS England (NHSE).

Ramsay share price bolstered by NHSE agreement

Like the previous agreement, the ASX-listed hospital group can continue providing private patient activity. This is a relief to investors as I will explain later.

The difference is the NHSE may trigger a "Peak Surge Period" on seven days' notice if it requires Ramsay to help manage a spike in COVID-19 cases. Should that happen, Ramsay will be paid on a cost recovery basis.

This agreement comes into effect from today and runs till 31 March. It may be extended by mutual agreement on or before 15 March.

COVID restrictions crimps the Ramsay share price

The surge in COVID cases is bad news for Ramsay's earnings as hospitals tend to make bigger profits from elective surgeries.

This is why the Ramsay share price has been under pressure recently. Its hospitals in New South Wales had to stop performing non-urgent treatments in response to the flood of patients with the Omicron COVID variant being admitted to hospitals.

Ramsay announced on Friday that the NSW Ministry of Health has put restrictions on overnight Category 2 and Category 3 elective surgery.

No light at the end of COVID tunnel

The move follows Victoria's Department of Health and Human Services (DHHS) decision to suspend non-urgent elective procedures.

Unlike the deal struck with NHSE, the restrictions imposed by NSW and Victorian health authorities have no end date. Ramsay and shareholders don't know when it can return to "business as usual".

The only silver lining is that January tends to be the quietest month for Ramsay Australia. Elective surgery patients rather lie in the sun than in hospital beds till after the school holidays end.

Foolish takeaway

Nonetheless, Ramsay has warned investors that it is expected to take a $55 million hit to earnings before interest and tax in the first quarter of this financial year.

This could change depending on how long the restrictions last and if NHSE triggers the Peak Surge Period.

Looks like it's too early to hope that the COVID cloud will start to dissipate in 2022.

The Ramsay share price is lagging behind other medical facility operators. Over the past 12-months, its shares have gained around 12%. But the Healius Ltd (ASX: HLS) share price and Sonic Healthcare Limited (ASX: SHL) share price have gained around 30% each.

This is because the latter two run COVID tests, something Australians can't seem to get enough of.

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »